Longitudinal Economic Burden for Non–Muscle-Invasive Bladder Cancer by EAU Progression Risk Groups Using the Prospective Multicenter COBLAnCE Cohort Linked to the French National Healthcare System Database
Take Home Message Costs of non-muscle invasive bladder cancer are highly heterogeneous and strongly influenced by disease severity and early treatment. Real-world, stage-specific estimates are essential for informing cost-effectiveness analyses and guiding health care decision-making.